Blog
How African American Patients Are Affected By Vasomotor Symptoms
African American women experience menopause within a broader context of biological, social, and structural influences that shape symptom burden and outcomes. In this segment, Genevieve Neal-Perry, MD, PhD, explains that vasomotor symptoms (VMS), including hot flashes and night sweats, affect up to 80% to 90% of menopausal women, with approximately one-third experiencing symptoms severe enough to disrupt daily functioning. These symptoms are closely linked to sleep disturbance, impaired work productivity, metabolic changes, and diminished overall quality of life.
Neal-Perry highlights findings from the Study of Women’s Health Across the Nation (SWAN), a large longitudinal cohort that characterized menopause experiences across diverse racial and ethnic groups. Contrary to earlier assumptions that hot flashes last fewer than 5 years, SWAN demonstrated substantially longer durations, particularly among African American women, who report VMS for more than 10 years on average. This extended duration, combined with higher severity, may contribute to downstream risks such as cardiovascular disease and cognitive decline.
The segment underscores the importance of evaluating menopause therapies across diverse populations. Neal-Perry emphasizes that pharmacologic response can vary by race, ethnicity, body composition, and other patient characteristics due to differences in drug metabolism and disease burden. Because African American women experience the highest frequency and longest duration of VMS, demonstrating therapeutic efficacy in this population is essential to ensuring equitable and effective menopause care.
Related Posts
Fionnuala McAuliffe, MD, highlights importance of timely breastfeeding discussions with patients
-
Posted by
mediamillion1000@gmail.com
- 0 comments
American Heart Association releases scientific statement for maternal stroke prevention during pregnancy, postpartum
-
Posted by
mediamillion1000@gmail.com
- 0 comments
American Academy of Pediatrics releases 2026 childhood immunization schedule
-
Posted by
mediamillion1000@gmail.com
- 0 comments
Cervical cancer screening adherence remains low in US patients
-
Posted by
mediamillion1000@gmail.com
- 0 comments
Practical Strategies for Integrating NK Receptor Antagonism for Vasomotor Symptoms into Primary Care
-
Posted by
mediamillion1000@gmail.com
- 0 comments
Final Thoughts on Vasomotor Symptoms and NK Receptor Antagonism
-
Posted by
mediamillion1000@gmail.com
- 0 comments
HMI-115 shows promising pain relief in endometriosis patients
-
Posted by
mediamillion1000@gmail.com
- 0 comments
First-trimester metformin use linked to pregnancy outcomes in PCOS patients
-
Posted by
mediamillion1000@gmail.com
- 0 comments
Beyond Vasomotor Symptoms: The Potential Role of NK Receptor Antagonism in Mood and Sleep
-
Posted by
mediamillion1000@gmail.com
- 0 comments
Positioning NK Receptor Antagonism in the Vasomotor Symptoms Treatment Landscape
-
Posted by
mediamillion1000@gmail.com
- 0 comments
American Cancer Society updates cervical cancer screening guidelines
-
Posted by
mediamillion1000@gmail.com
- 0 comments
Evaluating the Rapid Onset of Vasomotor Symptom Improvement and Safety Profiles of NK Receptor Antagonists
-
Posted by
mediamillion1000@gmail.com
- 0 comments